|1.||Doi, Takayuki: 2 articles (09/2014 - 07/2010)|
|2.||Luesch, Hendrik: 2 articles (07/2009 - 06/2008)|
|3.||Fujino, Yuta: 1 article (09/2014)|
|4.||Suzuki, Jun: 1 article (09/2014)|
|5.||Masuda, Yuichi: 1 article (09/2014)|
|6.||Yoshida, Masahito: 1 article (09/2014)|
|7.||Onda, Yuichi: 1 article (09/2014)|
|8.||Tidgewell, Kevin: 1 article (07/2010)|
|9.||Byrum, Tara: 1 article (07/2010)|
|10.||Gerwick, William H: 1 article (07/2010)|
06/13/2001 - "Apratoxin A (1) possesses IC(50) values for in vitro cytotoxicity against human tumor cell lines ranging from 0.36 to 0.52 nM; however, it was only marginally active in vivo against a colon tumor and ineffective against a mammary tumor."
09/05/2014 - "Total synthesis of apratoxin C, a cyanobacterial cyclodepsipeptide with highly potent cytotoxicity against some cancer cell lines, was achieved using the apratoxin A synthetic strategy developed by us. "
07/05/2010 - "Additional assays using zone inhibition of cancer cells and clonogenic cells give a comparison of the activities of apratoxin F to apratoxin A. "
02/01/2007 - "Recent advances include the discovery of novel small molecules regulating cell death pathways -- necrostatin and erastin -- as well as the elucidation of the mechanism of death induced in cancer cells by the cytotoxic agent Apratoxin A."
07/01/2009 - "Apratoxin A also depletes cancer cells of several cancer-associated receptor tyrosine kinases by preventing their N-glycosylation, leading to their rapid proteasomal degradation. "
|2.||Dehydration (Water Stress)
|5.||tyrosine receptor (receptor, tyrosine)